Takeda

This study tests a dengue vaccine in adults aged 45 to 79, including those with conditions like diabetes or high blood pressure. Participants receive two shots three months apart. The goal is to check safety and how well the vaccine triggers an immune response against all four de…

This study tracks 275 people in Japan who receive darvadstrocel injections for complex anal fistulas caused by Crohn's disease. Researchers will monitor side effects and check if the treatment helps close the fistulas over 36 months. The goal is to see if this cell therapy can im…

This study in Japan looks at how safe and effective Vonvendi (rVWF) is for children under 18 with von Willebrand disease, a bleeding disorder. About 13 kids will receive the drug as part of their normal care for bleeding episodes or before surgery. Researchers will monitor side e…

This study tests whether fazirsiran can reduce liver scarring (fibrosis) in people with Alpha-1 antitrypsin deficiency, a genetic condition that can cause serious liver disease. About 160 adults with moderate to severe liver scarring will receive either fazirsiran or a placebo fo…

This study looks at medical records of 50 people in Saudi Arabia with hereditary angioedema (HAE) who have been taking Takhzyro for at least 6 months to prevent swelling attacks. Researchers want to see if the drug reduces disease activity and improves quality of life in real-wor…

This study tests whether a combination of two drugs, vedolizumab and tofacitinib, can help adults with moderate to severe ulcerative colitis achieve remission. Participants receive both drugs for 8 weeks, then those who respond continue with vedolizumab alone for 44 weeks. The go…

This study tests a medicine called vedolizumab in children and teens with moderate to severe Crohn's disease. The goal is to see if the drug can keep symptoms under control and reduce gut inflammation over a year. Participants first receive three infusions over 6 weeks, then thos…

This program provides ongoing access to an unlicensed treatment called recombinant von Willebrand factor (rVWF) for people with severe von Willebrand disease who have already benefited from it in a previous study. It is for both children and adults who have completed at least 12 …

This study looks at whether vedolizumab can help people with moderate to severe ulcerative colitis or Crohn's disease achieve remission (no symptoms) after 14 weeks of treatment. About 400 adults aged 18 to 80 will receive vedolizumab first as an IV infusion, then as a shot under…

This study tests TAK-411, a specially modified antibody, in 36 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), an autoimmune disease that attacks nerve coverings and causes muscle weakness. The goal is to see if TAK-411 can improve physical function …

This study looks at how HyQvia, a treatment to boost the immune system, is used in real-world clinics for people with multiple myeloma who have a weakened immune system (secondary immunodeficiency). Researchers will track details like dose, infusion speed, and where the treatment…

This study tests a new oral drug called zasocitinib (TAK-279) for adults with active psoriatic arthritis who have not tried biologic treatments. About 1,088 participants will receive either the new drug, an active comparator, or a placebo for up to 60 weeks. The main goal is to s…

This program offers continued access to vedolizumab, given as an IV infusion, for children and teenagers with moderate to severe ulcerative colitis or Crohn's disease who completed a prior study and still benefit from the treatment. It is designed for those without suitable alter…

This study tests a drug called maribavir in Chinese adults who have had a stem cell or organ transplant and have a CMV infection that no longer responds to standard treatments. The main goal is to see if maribavir is safe and well-tolerated, and also how well it clears the virus.…

This study tests the long-term safety of a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. About 150 participants who were in earlier mezagitamab studies wil…

This study looks at the long-term safety of the drug vedolizumab in children with ulcerative colitis or Crohn's disease. It is for kids who already completed a previous vedolizumab study. Researchers will track side effects and major bowel-related events over time.

This study tests a new drug called elritercept against a standard treatment (epoetin alfa) for anemia caused by a bone marrow disorder called myelodysplastic syndromes (MDS). About 300 adults who need regular red blood cell transfusions will take part. The goal is to see if elrit…

This study tests a new drug called elritercept (KER-050) in about 135 adults with myelofibrosis, a rare bone marrow cancer. The drug is given alone or with the standard medicine ruxolitinib. The main goals are to check safety and see if it helps with anemia and other symptoms. Th…

This study is monitoring the long-term safety and effectiveness of the drug leuprorelin in people with spinal and bulbar muscular atrophy (SBMA), a rare muscle-weakening disease. Researchers will follow about 1,890 patients in routine medical care for up to 8 years, tracking side…

This study tests whether combining two different drugs (vedolizumab with either adalimumab or ustekinumab) can better control moderate to severe Crohn's disease. About 100 adults will receive the combination for 26 weeks, then those who respond will switch to vedolizumab alone. T…

This study tests a new drug called TAK-505 for the first time in people with advanced solid tumors that cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink or slow tumor growth. About 151 adults with certain ca…

This study tests a drug called vedolizumab in Chinese adults with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. About 402 participants will receive either the drug or a placebo to see if it reduces sym…

This study looks at the long-term safety of a drug called vedolizumab in children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who responded well to the drug in an earlier study will continue treatment, while others who did not respond well will…

This study tests a drug called mezagitamab in adults with IgA nephropathy, a kidney disease caused by protein buildup and inflammation. The main goal is to see if it lowers protein in urine (a sign of kidney damage) better than a placebo. About 347 participants will receive eithe…

This study tests a new drug called TAK-330 to reverse the effects of blood thinners (Factor Xa inhibitors) in people who need urgent surgery. About 328 adults on these blood thinners will be randomly assigned to get TAK-330 or standard reversal treatment before their procedure. T…

This study looks at the long-term safety of the drug TAK-861 in 500 people with type 1 narcolepsy who have already taken it in a previous study. Researchers will track side effects and measure how well patients can stay awake. The goal is to see if the drug remains safe and toler…

This study tests an oral drug called TAK-279 in 268 adults with moderate to severe Crohn's disease who haven't responded well to other treatments. The main goal is to see if three different doses can reduce bowel inflammation and ulcers after 12 weeks compared to a placebo. Parti…

This study tests if a new drug, TAK-881, works as well as an existing treatment, HYQVIA, for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a nerve condition causing weakness and numbness. About 59 participants who already receive immunoglobulin the…

This study looks at how maribavir is used and how well it works for adults who get a common virus called CMV after an organ or stem cell transplant. Researchers will follow 75 people in Belgium for up to 2 years, collecting data from regular doctor visits. The goal is to see if t…

This study looks at the long-term safety of an oral medication called zasocitinib (TAK-279) for people with moderate to severe Crohn's disease or ulcerative colitis. Participants who responded to treatment in earlier studies can continue taking the drug for up to 2 years. The mai…

This study looks at how well the drug teduglutide works in children aged 1 to 17 with short bowel syndrome who rely on IV nutrition. The goal is to see if the drug can reduce the amount of IV nutrition needed or help some children stop it completely. Researchers will review medic…

This study is for adults in India with untreated stage 3 or 4 Hodgkin lymphoma. It tests a drug called brentuximab vedotin combined with standard chemotherapy (AVD) to see how safe and effective it is. Participants receive treatment for about 6 months and are monitored for side e…

This early-stage study tests whether the drug TAK-781 is safe and tolerable. First, healthy volunteers receive either the drug or a placebo. Then, people with primary sclerosing cholangitis (PSC) receive the drug. The study also looks at how the body processes TAK-781. About 134 …

This program offers continued access to idursulfase-IT (TAK-609) given directly into the spinal fluid, along with intravenous Elaprase, for children and adults with Hunter syndrome who have cognitive impairment. Participants must have completed one of two earlier studies. The goa…

This study tests whether giving immune globulin (IGI) regularly can prevent serious infections in people with multiple myeloma who are receiving a type of immunotherapy called bispecific antibodies. About 183 adults will be randomly assigned to receive IGI for 12 months from the …

This study tests a drug called fazirsiran in people with Alpha-1 antitrypsin deficiency who already have mild liver scarring. The drug aims to reduce the buildup of a faulty protein that damages the liver. About 50 participants will receive either fazirsiran or a placebo for 2 ye…

This study tests a subcutaneous (under-the-skin) version of vedolizumab in children aged 2-17 with moderate to severe ulcerative colitis or Crohn's disease. About 70 kids who already responded to IV vedolizumab will receive the shot for up to 34 weeks. The goal is to see how the …

This study looks at how well the drug brentuximab vedotin (BV) works for adults with Hodgkin's lymphoma who have had a stem cell transplant. The goal is to see if BV can help prevent the cancer from coming back. About 70 participants will receive BV as part of their regular care …

This study tests a medicine called zasocitinib in children and teens aged 4 to 17 with moderate-to-severe plaque psoriasis. The goal is to see how well it clears skin and if it is safe. Participants will take the medicine or a placebo for 16 weeks, then all will get the real medi…

This study tests a drug called vedolizumab for people in China with moderate to severe Crohn's disease, a condition that causes inflammation in the gut. About 408 adults will receive either the drug or a placebo to see if it reduces symptoms like belly pain and diarrhea. The goal…

This study follows 30 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are switching to the treatment HyQvia. Researchers will collect information from medical records, interviews, and questionnaires to understand why patients chose HyQvia, how sat…

This study tests an investigational drug called elritercept in adults with a bone marrow disorder (MDS) who need regular red blood cell transfusions. The main goal is to see if the drug can help patients go at least 8 weeks without a transfusion. About 225 participants will recei…

This study tests a new oral drug, zasocitinib, for moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful, deep bumps and abscesses. About 90 adults will receive either the drug or a placebo for 4 months, then all will get the drug for up to 8 more mon…

This study tests a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The drug is given as a shot under the skin for up to 6 months. The goal is to see if it can keep platel…

This study tests a daily pill called zasocitinib for adults with nonsegmental vitiligo, a condition where the immune system attacks pigment cells, causing white patches. About 200 participants will receive either the drug or a placebo for up to a year. The goal is to see if the d…

This study tests a drug called VONVENDI (recombinant von Willebrand factor) to see if it is safe and helps control bleeding in Chinese adults with von Willebrand disease (VWD), a condition that makes blood clot poorly. About 20 participants will receive the drug, sometimes with a…

This study tests an experimental drug called elritercept (KER-050) in about 160 adults with a bone marrow condition called myelodysplastic syndromes (MDS) who have anemia. The main goal is to check the drug's safety and how well people tolerate different doses. Researchers will a…

This study in Japan tracks 250 organ or stem cell transplant patients whose CMV infection hasn't cleared with standard treatments. They will take Maribavir tablets as part of their normal care, and doctors will watch for side effects and check if the virus clears from the blood o…

This study tests a new medicine called TAK-755 in adults who have had a stroke caused by a blood clot. The goal is to see if it is safe and helps people recover better than standard care alone. About 222 participants will receive either TAK-755 or a placebo once, and their health…

This study watches how well the enzyme replacement therapy Replagal works for Chinese children and adults with Fabry disease, a rare inherited disorder that causes harmful fat buildup in organs. Researchers will track changes in heart and kidney function, quality of life, and saf…

This study tracks side effects in children and teenagers with untreated Hodgkin lymphoma who receive ADCETRIS along with standard chemotherapy (AVD). Researchers will monitor for serious side effects like low blood counts, nerve damage, and lung problems over 26 weeks. The goal i…

This study tests a drug called vedolizumab in children with chronic pouchitis, an inflammation of an internal pouch created after bowel surgery. About 30 children will receive up to 12 infusions over about 18 months. The goal is to see if the drug can reduce symptoms and pouch in…

This study tracks the safety of a drug called ADZYNMA in 40 people with a rare blood disorder (congenital TTP) in Japan. Doctors will monitor side effects and check if the drug helps prevent or treat TTP episodes over 18 months. Participants receive the drug as part of their norm…

This study looks at the long-term safety and effectiveness of the drug zasocitinib for adults with psoriatic arthritis, a condition that causes joint pain and skin problems. Participants who completed a one-year study on this drug can join and will take zasocitinib daily for up t…

This study tests a new medicine called TAK-861 for people with narcolepsy type 1, a condition that causes sudden sleep attacks and muscle weakness (cataplexy). About 88 adults will take the drug for a few months, then some will switch to a placebo to see if their symptoms return.…

This study tracks side effects, especially lung-related ones, in 500 Japanese adults with a specific type of non-small cell lung cancer. Participants take Brigatinib tablets as part of their normal care, and doctors record any health issues for one year. The goal is to better und…

This study tests a new drug called vonicog alfa in 24 children with severe von Willebrand disease, a condition that causes easy bruising and bleeding. The drug is given regularly for 12 months to see if it reduces bleeding episodes. Participants will visit the clinic 5 times duri…

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to fight cancer more effective…

This study monitors how safe and effective the drug LIVTENCITY (maribavir) is for adults who develop CMV infection after an organ transplant. About 168 participants in South Korea will be followed for 20 weeks during routine care. The goal is to see how well the drug works in eve…

This study tests the drug fruquintinib in 78 adults from minority groups (Black/African American and/or Hispanic/Latino) with advanced colorectal cancer that hasn't responded to other treatments. The main goal is to see how often severe high blood pressure occurs as a side effect…

This study is testing whether a new oral medication called zasocitinib can help control the symptoms of active psoriatic arthritis, a condition that causes joint pain and skin plaques. About 600 participants will be randomly assigned to receive one of two doses of the drug or a p…

This study tests a new medicine called TAK-360 for people with idiopathic hypersomnia (IH), a condition that causes extreme sleepiness even after lots of sleep. The drug works like a brain chemical called orexin that helps keep you awake. Researchers want to see if TAK-360 is saf…

This study tests whether a daily medicine called dexlansoprazole can ease heartburn and other symptoms in children aged 2 to 11 who have GERD but no damage to their esophagus. About 70 kids will take the drug or a placebo for 12 weeks, and parents or children will report symptoms…

This study tests if the drug vortioxetine can safely reduce depression symptoms in Japanese teenagers aged 12 to 17 with major depressive disorder. About 180 participants will receive either the drug or a placebo for 14 weeks, with follow-up for 4 more weeks. The goal is to see i…

This study tests a new drug called TAK-360 for people with narcolepsy type 2, a condition that causes severe daytime sleepiness. The drug acts like a natural brain chemical (orexin) that helps keep you awake. About 88 adults will receive either TAK-360 or a placebo to see if the …

This study looks at how much of the constipation medicine prucalopride gets into breast milk. Researchers will collect milk samples over 24 hours from 12 women who take the drug. They will also track the growth and health of the babies for one year to check for any side effects.

This study follows 500 adults with alpha-1 antitrypsin deficiency (AATD) for up to 5 years to see how their liver disease changes over time without any special treatment. Researchers will collect medical history, yearly questionnaires, and tests to track liver scarring and other …

This study looks at medical records of 10 adults who had a transplant and later got a CMV infection that was hard to treat, along with severe kidney disease or kidney failure (including those on dialysis). The goal is to see if the drug maribavir caused any side effects. No new t…

This study monitors the safety and effectiveness of brigatinib in adults with advanced ALK-positive non-small cell lung cancer in South Korea. Researchers will track side effects and tumor response in 257 patients who start brigatinib for the first time. The goal is to see how we…

This study uses a survey to check how well patients and doctors understand the risks and required monitoring for GATTEX, a medicine for Short Bowel Syndrome. About 600 people (adults who have taken GATTEX recently and their healthcare providers) will answer true/false questions o…

This study looks at how often liver problems happen in children with Alagille syndrome or progressive familial intrahepatic cholestasis who take the drug Livmarli. Researchers will use a Japanese registry of childhood liver disease to track about 50 patients. The goal is to bette…

This study observes 600 adults with colorectal cancer who are already taking the drug fruquintinib as part of their normal care in South Korea. The goal is to track any side effects and see how many patients are alive and without cancer growth after 6 months. No new treatments or…

This study aims to find out how many people in Spain have been diagnosed with narcolepsy type 1 or type 2, and how many new cases are diagnosed each year. Researchers will review medical records from hospitals across Spain to count patients and understand patterns. The study does…

This study reviews medical records of 40 children aged 2 to 12 with hereditary angioedema (HAE) who have taken lanadelumab (Takhzyro) to prevent swelling attacks. Researchers will measure how many children stay attack-free and track treatment patterns, safety, and healthcare use.…

This study looks at how well the dengue vaccine works in real life for children and teens in Thailand, Indonesia, and Malaysia. Researchers will follow 70,000 participants for up to 3 years to see if those who got the vaccine are less likely to be hospitalized with dengue. The go…

This study looks back at medical records of about 100 people in Japan with primary immunodeficiency who received Cuvitru. The goal is to track serious side effects like allergic reactions, blood clots, and meningitis. No new treatments are given—just a review of existing data to …

This study is tracking 600 adults in South Korea who are already receiving vedolizumab injections for ulcerative colitis or Crohn's disease. Researchers will review medical records to see what side effects occur and how well the treatment works. No new treatments are given—this i…